BridgeBio Drug Acoramidis Shows 44% Cut in Heart-Related Deaths

BridgeBio Pharma on Saturday unveiled compelling new long-term data for its heart drug acoramidis, showing a significant reduction in cardiovascular mortality for patients with a rare and serious heart condition. The findings, presented at the European Society of Cardiology Congress in Madrid, are a major step in establishing the drug as a leading treatment for transthyretin amyloid cardiomyopathy (ATTR-CM).

In an open-label extension of its Phase 3 clinical trial, acoramidis demonstrated a 44% reduction in the risk of cardiovascular death over a 42-month period. The study also showed a 46% reduction in the combined risk of cardiovascular death or first hospitalization, reinforcing the drug's sustained benefit for patients.

"These results...add to the growing body of evidence supporting acoramidis as a potentially transformative therapy for patients with ATTR-CM," said Dr. Kevin Alexander of Stanford University School of Medicine, who presented the findings. He highlighted the drug's "meaningful impact on patient outcomes" and its role in addressing a critical unmet need.

ATTR-CM is a progressive and fatal disease caused by the buildup of unstable proteins in the heart. Acoramidis works by stabilizing these proteins. The new data also indicated that patients treated with the drug had higher rates of disease stabilization or improvement compared to those who initially received a placebo.

The drug, marketed as Attruby in the United States and BEYONTTRA in Europe and other regions, has already received regulatory approval. This latest data is expected to bolster its commercial prospects and strengthen its position against competing treatments. BridgeBio has a licensing agreement with Bayer to commercialize the drug in Europe, further expanding its market reach. The company plans to present additional data at future medical meetings.